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1. Introduction  
Autoimmune diseases are a complex group of diseases arising because of the breakdown of 
narrow margin that exists between the immunity and tolerance. In simpler terms either T or 
B-cells or both are activated in the absence of a progressive infection or any other noticeable 
cause (Davidson & Diamond, 2001). Unable to distinguish self from non self, the renegade 
immune cells pose a serious threat to self molecules leading to severe destruction.  The 
precise mechanisms that drive this event are still unclear but, most of the studies identified 
that genetics, environment and infections will have a role in triggering the autoimmune 
attack (Smith et al., 1999). An approximate of 5% of the population in western countries are 
currently the victims of these diseases and in this component, a major proportion of them 
are females displaying a higher risk of incidence (Jacobson, 1997; Kanwar, 2005). Added to 
this, the general ailments of the humans like atherosclerosis and gastrointestinal 
disturbances are found to be associated with an autoimmune component, predisposing the 
risk of developing an autoimmune disease (Ross, 1990, Galperin & Gershwin 1997).The 
influence of hormones cannot be neglected as preclinical studies have witnessed the role of 
oestrogen in the emergence of autoimmune diseases while testosterone was found to lower 
the risk in lupus prone mice (Sakic, 1998; Roubinian et al., 1978). Few epidemiological 
studies also revealed the preponderance of autoimmune diseases mediated by the nocturnal 
hormone, melatonin (Cutolo, 2003). In addition, cortisol levels and the secondary events like 
stress were also found to influence the autoimmune disease generation (Webster et al, 1998).  
Since ages, the basic principle of immunology has been the concept of clonal deletion of 
autoreactive immune cells and generation of a mature T & B-cell repertoire that could 
distinguish self from non self. The formation and survival of mature immune repertoire, 
always demands prolonged auto antigen exposure acknowledging the physiological 
importance of autoreactivity (Goldrath & Bevan, 1999; Gu et al., 1991). Though structural 
resemblances exist between self and non self antigens the attack is directed against self 
antigens under stimulatory conditions like the presence of infections, cytokines etc 
(Silverstein & Rose, 2000; Kanwar, 2005; Kanwar et al, 2009). Thus it is always fascinating to 
find answers for how the physiology of autoimmunity is turned to pathology and how the 
immune cells enforce their attack. This review focuses on introduction to immunity, 
pathology of autoimmune diseases and their treatments along with recent advancements. 
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2. Basics of immune system 
The immune system comprises of a complex array of immune cells tailored to defend the 
body against a variety of substances that are considered as foreign including pathogenic 
microbes and tumors while remaining nonreactive towards the self. Immune cells are 
originated from the haematopoietic stem cells and are classified as lymphoid and myeloid 
cells comprising B & T-lymphocytes, Natural killer cells (NKs), dendritic cells and 
polymorphonuclear leukocytes, monocytes, mast cells, macrophages respectively (Delves, 
2006). The immune cells constantly patrol the body and involve specific and non specific 
mechanisms in executing immune attack upon finding a foreign substance. The specificity 
rests particularly with T and B-cells as they display the receptors capable of recognising non 
self molecules from the self.  
The specific attack is also complimented before by the strategic non specific immune 
responses generated by polymmorphonucelar cells, NKs, macrophages, co-stimulatory 
molecules like cytokines and serves as the initial site of attack upon finding the foreign 
entities. The abnormal levels of cytokines have a strong impact in the initiation and 
progression of autoimmune diseases. Also, therapeutic interventions with exogenous 
cytokines were found to be associated with the disease process, suggesting their key role in 
mediating the disease (Hooks et al., 1982; Trembleau et al., 1995; McKall-Faienza et al., 1998;  
Schattner, 1994; Kanwar et al, 1999; Kanwar et al, 2005; Kanwar et al, 2009). The complex 
network of immune cells is classified into subpopulations based on the expression of surface 
markers, functional characteristics, regions where they mature and activate. Likewise, T-
cells include helper cells (Th) displaying CD4+ marker and involve in modulating the 
immune responses. Further they comprise subsets of Th1 cells that aid other T-cells and Th2 
subtype mediates the antibody generation.  Cytotoxic cells (Tc) with CD8+ marker are killer 
cells with lethal effect on intracellular pathogens, infected and tumor cells. Lastly, 
suppressor cells (Ts) down regulate and monitor the immune reactions. The naive T-cells 
undergo maturation in the thymus (hence the name T-cells) and are able to respond only to 
the processed antigens. Most of the nucleated cells of the mammalian system function as the 
antigen presenting cells (APCs) and dendrites are unique in this category expressing major 
histocompatibility complex proteins (MHC) and generating co stimulatory gestures for T-
cell activation. APCs process the antigen and represent them in association with cell surface 
MHCs for T-cell recognition. These MHCs categorised as class I and Class II are crucial in 
the selection process of cytotoxic and helper cells respectively. 
The T-cells bear an antigen recognition site on their surface called as T-cell receptor (TCR) 
and the initiation of T-cell mediated immunity requires the complex association of the 
antigen, MHC and the TCR. B-cells are specialised immune cells that act as APCs along with 
a prime function of antibody generation. The immature B-cells initially express a pre-B cell 
receptor (pre-BCR) on their surface and upon maturation they produce antibodies that act as 
antigen receptors towards the native antigen (Yang & Santamaria, 2006; Austyn, 2000; Roitt 
et al., 1998; Janeway & Travers, 1998).  Both the T and B-cells express specific receptors for 
each antigen and this diversity is exhibited by the rearrangement of receptor gene sequences 
in the somatic cells rather than acquired through the inheritance (Gellert, 2002). In order to 
mount immune responses, the T and B-cells are activated through corresponding receptors 
in the presence of co-stimulatory molecules (Crow, 2004; Kanwar et al, 2000; Kanwar et al, 
2003; Kanwar et al, 2005). Another essential feature of both these cells is that, upon initial 
exposure to an antigen both these cells generate memory cells that expand clonally. These 
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memory cells unleash an accelerated immune attack upon antigen re-exposure (Swain, 2003; 
Bishop et al., 2003). 
3. Tolerance 
Because of the expression of vast diversity of antigen recognition sites on T and B-cells, 
molecules that are considered as self also may find chances of binding with the immune 
cells. Hence, a diverse range of tolerance mechanisms have been developed that train the T 
& B-cells to differentiate self from nonself. This process is tightly controlled in the primary 
lymphoid organs and is continuous to inhibit the various modes of auto reactive 
lymphocyte generation and activation. The basic mechanisms dealt are clonal deletion, 
clonal anergy and inhibition of self reactive lymphocytes (Yoshida & Gershwin, 1993; 
Rajewsky, 1996). 
3.1 T and B cell tolerance 
The tolerance mechanisms that develop in the primary lymphoid organs like thymus and 
bone marrow respectively for T and B cells constitute central tolerance. The naive T-cells 
originated from haematopoietic stem cells are devoid of CD4 and CD8 cell surface markers. 
Once migrated to the thymus, the TCR gene rearranges to develop double positive T-cells 
that display CD4+ and CD8+. Then these cells are positively selected as CD4+ and CD8+ cells 
based on their interactions with the MHC class II and Class I respectively. The cells with 
TCR, that fail to bind or interact MHC with little affinity undergo death and are positively 
selected based on weaker interactions between TCR and MHC carrying self antigens. T-cells 
are killed if found to interact strongly with a self antigen displayed by MHC and thus 
selected negatively (Palmer, 2003; Starr, 2006; Bretscher & Cohn, 1970; Kanwar et al, 2004; 
Kanwar, 2005). As a matter of enhanced protection from immune attack, the T-cells 
receiving stronger signals through TCR are deleted and this inactivation is much more 
sensitive compared to activation of T-cells that demand a stronger interaction between TCR 
and self antigen-MHC complex (Kappler, 1987; Pircher et al., 1991; Yagi & Janeway, 1990). 
Similar tolerance mechanisms exist for B-cell repertoire, as they are negatively selected if the 
BCR is found to interact strongly with the self antigens. However, active investigation is 
recommended to determine the existence of positive selection for B-cells. Interestingly, 
successful T-lymphocyte tolerance cuts down the signals for few autoreactive B-cells and 
thus induces B-cell tolerance (Bretscher & Cohn, 1970). During the course of their 
maturation, the pre B-cell receptor (BCR) cross links several avid auto-antigens. This event 
stimulates the rearrangement of light chain genes of the Ig’s thus, driving the process of 
receptor editing where self antigens are replaced with non self ones (Ana et al., 2010). B-cells 
are deleted by apoptotic mechanism if found to interact strongly with self antigens (this 
happens mostly in bone marrow) and anergised if bound with little affinity (this happens 
mostly in periphery) (Monroe et al., 2003; Hodgkin & Basten, 1995). T-cells have a potential 
role in the generation and progression of chemical and spontaneously induced autoimmune 
diseases and the same was also demonstrated successfully in the animal studies (Singer & 
Theofilopoulos, 1990; Druet, 1989; Pettinelli & McFarlin, 1989; Waldor et al., 1985). Few 
autoreactive T-cells may escape tolerance mechanisms and spread in the periphery but, they 
are naive and do not hold any threat unless APCs turn active. Potential problem persists 
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incase of molecular mimicry (where pathogenic antigens resemble self antigens) as APCs 
turn active and trigger T-cell attack that is indiscriminate towards self and nonself. The same 
also holds true for B-cells (Damian, 1964; Oldstone, 1998). On the whole, generation of 
autoimmune diseases is based on the narrow margin that exists between tolerance and 
immunity executed by deletion and survival of self reactive lymphocytes. Too much 
deletion compromises the immunity and too little deletion follows subsequent 
autoimmunity. The following figure is an ideal representation of healthy and pathologic 
immunity and the differentiation between tolerance and autoimmunity. 
 
 
Fig. 1. Showing the comparison of healthy and pathologic immune system. A healthy T-cell 
upon exposure to self antigens undergo specific mechanisms of inactivation like deletion or 
clonal anergy constituting peripheral tolerance while an autoreactive T-cell is dysregulated 
with indiscriminate attack on self and non self antigens because of the lack of tolerance in 
autoimmunity. 
4. Autoimmune triggers 
4.1 Genetics 
The enhanced knowledge of the mammalian immune system and the genetics lead to 
understanding the role of genes in autoimmune diseases. In the case of disease pathology, 
genetic variations are found to affect the MHC and several immunological pathways that in 
turn lead to the stimulation of autoimmunity. A number of studies have evidenced the 
potential role of genetics in the disease generation. Twin studies of multiple sclerosis (MS), 
rheumatoid arthritis (RA), Type- 1 diabetes and systemic lupus erythematosus (SLE) have 
reported a marked genetic predisposition of which the risk factor was found to be higher for 
monozygotic twins than the dizygotic twins. The risk of inheriting the systemic autoimmune 
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diseases was also reported and this etiology could be due to the family history associated 
with the genetic vairaitons. In addition, a variety of MHC and non-MHC susceptible genes 
are identified in the genome wide studies of MS, SLE and RA while, few studies reported 
that many autoimmune diseases have a common genetic etiology operating (Glinda, 1999). 
Likewise, the association of intracellular tyrosine phosphatise, PTPN22 was shared in the 
pathologies of Type-1diabetes, RA and myasthenia gravis (Bottini, 2004; Begovich, 2004; 
Vandiedonck et al., 2006). In brief, genetics underscore a significant risk factor for the 
autoimmune etiology and presents a new area to explore. 
4.2 Auto antigens 
In the early stages of development some of the self antigens might escape recognition from 
the T-cell populations. This could happen because, they might not have been formed at the 
time of T-cell development or they might be separated from T-cell access due to remote 
anatomical existence (e.g. myelin basic protein) or due to the presence of membrane barriers 
or they might be inappropriately presented by the MHC proteins (Manoury, 1998). These 
cryptic antigens hinder the tolerance mechanisms and drive the autoimmune attack if they 
are encountered by the T-cells upon membrane barrier disruption for e.g. orchiditis upon 
vasectomy (Flickinger, 1994; Jarow et al., 1994) infections (Type 1 diabetes upon coxsackie B 
virus infection) or any other mechanism that exposes them (Yoon et al., 1979). A striking 
feature of auto antigens is that they are not specific to any tissue and form the integral 
components of all various cell types (Tan et al., 1987). 
4.3 Role of infections 
Infections have an interesting role to play in the induction of autoimmune diseases and 
there are several interesting mechanisms where infections mediate them. In the instances of 
microbial infections, immune cells cannot differentiate antigenic sequences from self 
proteins if structural similarities are found. This molecular mimicry unleashes the immune 
attack that is directed towards self and nonself leading to tissue destruction. For e.g. 
hepatitis B virus polymerase resembles myelin basic protein and generates auto antibodies 
that destroy myelin leading to multiple sclerosis (Fujinami & Oldstone, 1989; Oldstone, 
1998; Fujinami & Oldstone, 1985). Infections are associated with interesting mechanisms that 
may enhance the severity of autoimmune diseases. Among these, epitope spreading is an 
instance where in an inflammatory burst, the avid APCs over process and presents the 
antigens to activate the large T-cell populations lowering the threshold to the disease onset. 
The other mechanism is termed as polyclonal activation where abundant B-cell populations 
are activated generating loads of antibodies along with immune complexes that pose serious 
threat to the tissues. The next mechanism involves the over activation and indiscriminate 
expansion of self reactive T-cells that are initially considered to be inefficient but can cause 
the disease in the presence of elevated levels of cytokines. Finally, microbes express super 
antigens on their surfaces that are unique in coupling T-cells with MHC complexes 
irrespective of their relativities (Barzilai et al., 2007a, 2007b). On the contrary when 
correlations were made between autoimmune diseases and infections, the incidences were 
found to be increased in the subjects who are at reduced risk of infections. The same holds 
true as autoimmune diseases have a rampant growth in western countries where the 
infectious incidences are lower compared to less developed nations (Bach, 2002; Patterson et 
al., 1996) substantiating the concept of hygiene hypothesis which states that the microbial 
exposure enhances the body’s defence mechanisms ( Bjorksten B, 1994). 
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4.4 Role of cell adhesion molecules 
The propagation of autoimmune attack desperately needs the in and out migration of the 
immune cells, in particular T-cells, into the susceptible environment with potent 
inflammatory mediation. Cell adhesion molecules provide a suitable platform for this 
setting and are categorised as integrins, immunoglobulins and the selectins (Ziff, 1991). An 
autoimmune inflammatory setting leads to the enhanced expression of vascular endothelial 
proteins that constitute mucosal addressin cell adhesion molecule-1 (MAdCAM-1), 
intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-
1). Correspondingly, the lymphocytes express the cell surface molecules P-selectin 
glycoprotein ligand-1 (PSGL-1), leukocyte function-associated antigen-1 (LFA-1) and very 
late antigen-4 (VLA-4) on their surface facilitating the adherence and entry of the immune 
traffic into the lesions and further enhancing the autoimmune spread (Dedrick  et al., 2003; 
Kanwar et al., 1999).VLA-4 and LFA-1are specifically expressed by the human B cells (Alter 
et al, 2003) and therapeutic interventions with anti-adhesion molecule antibodies have 
witnessed successful termination of autoimmune disease severity in preclinical and clinical 
models (McMurray, 1996; Kanwar et al, 2000; Kanwar et al 2003; Kanwar, 2005; Kanwar et al 
2009). 
 
 
Fig. 2. Showing a typical T-cell exhibiting the phenomenon of rolling, adhesion and 
migration through the blood brain barrier (BBB) into the CNS. T-cell expresses PSGL-1, 
VLA-4 and LFA-1 on its cell surface and rolls over to adhere to the corresponding cell 
adhesion molecules, mucosal addressin cell adhesion molecule  (MAdCAM), Vascular cell 
adhesion molecule (VCAM) and Intracellular cell adhesion molecule, (ICAM) respectively 
on the blood brain barrier capillary endothelial cells. These cell surface ligands are over 
expressed in an inflammatory condition facilitating the entry of T-cells into the BBB and 
thus initiating an autoimmune cascade. 
4.5 Long lived plasma cells 
The concept of long lived antibody secreting plasma cells were first demonstrated in a 
mouse model immunized with ovalbumin where in the plasma cells secreted antibodies 
against ovalbumin and the production was continuous independent of antigen exposure 
and memory cell assistance (Manz et al., 1997, 1998). The same was also observed in another 
mouse model infected with lymphocytic choriomeningitis virus (Slifka et al., 1998). The 
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potential role of long lived plasma cells in the generation of autoimmune diseases was 
studied in NZB/W mice that served as a model for systemic lupus erythematosis (Hoyer et 
al, 2004). The differentiation of B-cells leading to the generation of memory cells and 
antibody secreting plasma cells is guided both by the antigenic and non antigenic stimuli 
(Tarlinton et al., 2008; Radbruch et al., 2006). However not all antibody secreting plasma 
cells turn long lived as it entirely depends on the antibody titre maintenance for the 
generation of secondary immune responses (Manz et al., 2005). 
Long lived plasma cells mainly originate from the germinal centre regions and require a 
close reciprocation of the T and B-cells. But, once generated these cells act independently. In 
one of the autoimmune pathologies, it was found that self reactive B-cells are not excluded 
from the germinal centre region allowing the production of long lived plasma cells that were 
autoreactive (Cappione et al., 2005). This concept of long lived plasma cells is novel and 
serves as attractive targets for treating autoimmune diseases. 
4.6 Auto antibodies  
The role of auto antibodies in the pathogenesis of autoimmune diseases is often elusive but 
considering few autoimmune diseases like myasthenia gravis, the antibodies are specific to 
cell surface receptors. The basic principle for the autoantibody directed cytotoxicity is the 
identification of cell surface antigen followed by cell death mechanisms either through 
complement activated system, antibody dependent cell mediated cytotoxicity (ADCC) or by 
the macrophage uptake mechanism (Ohishi et al., 1995; Frisoni et al., 2005). Complement 
activated system is constituted by a collection of specific group of plasma proteins and are 
considered to be more prevailing in autoimmune diseases. The class of autoimmune 
haemolytic anaemia, lupus syndrome typically fall under the complement system generated 
autoimmune diseases (Fang et al., 2009). In the case of classical ADCC, NKs play a prime 
role in mediating the cell death, after the binding of antibody with the target antigen. NK’s 
binds the Fc portions of these antibodies and induce cell death by free radical generation. 
Autoimmune thyroid disease is a fine example of ADCC mediated autoimmune disease 
(Rodien et al., 1996). Finally, macrophages execute the uptake and cell lysis processes once 
they find the appropriate antibody-antigen interaction (Gehrs & Friedberg, 2002). In general, 
the auto antibodies are directed to intracellular antigens and this understanding unveils 
fascinating questions of how they interact with intracellular antigens. The possible 
explanation could be because of the cross reaction of surface antigens with the intracellular 
antigens (Frisoni et al., 2005) and the exposure of intracellular components after lysis due to 
an impaired macrophage phagocytosis (Hansen et al., 2002). The potential significance of 
auto antibodies in autoimmune diseases were also demonstrated in the foetus as few of the 
immunoglobulin’s (IgG) can cross the placenta and target the cell surface creating a havoc of 
tissue destruction (Clancy et al., 2004a, 2004b). Also, the apoptotic cells were found to be 
potent enough to generate autoantibodies if accompanied by other moieties like dendritic 
cells or Freunds incomplete adjuvant. These dying cells tend to activate Toll like receptors 
and NF-kB pathway that are associated with inflammation which in turn is linked to 
generation of autoantibodies (Bondanza et al., 2004), in conclusion it has to keep in mind 
that, auto antibodies are not always associated with the disease and few of them are 
valuable diagnostic aids implicated in a clinical setting. 
4.7 Stress and autoimmune diseases 
Stress of both versions physical and physiological is found to be associated with the disease 
generation. This was also supported from the several past studies that emotional stress was 
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highly proportionate for predicting the disease onset. These two are related because, stress 
presumably shoots the neuroendochrine triggers that are predicted to alter the immune 
function or the cytokine levels ending up with the disease generation (Herrmann et al., 2000;  
Stojanovich & Marisavljevich, 2008). Also, stress induces the expression of heat shock 
proteins that are highly immunogenic with a potential of triggering autoimmune diseases 
(Kanwar et al., 2001). Therefore, therapeutic interventions for these diseases should consider 
management of emotions and stress.  
4.8 Pregnancy and autoimmune diseases 
In order to escape the immune attack neither the sperms nor the developing trophoblast 
bear the MHC proteins of either class. This peculiar feature allows the escape and survival 
of the sperm from the immune attack to fertilize the ovum (Johnson, 1993). Soon after 
fertilisation, many protective measures are adopted to protect the developing foetus and 
likewise it bears the human leucocyte antigen (HLA-G) marker which if otherwise would 
have been killed by the natural killer cells (VanVoorhis & Stovall, 1997). Also regulatory 
proteins from the foetus avoid the activation of complement system and its subsequent 
attack (Holmes & Simpson, 1992). Interesting immunological features are noticed in a 
pregnant woman, as changes are seen in the immune reactions that shift from Th1 to Th2 
type due to the release of cytokines like TGF-beta (Raghupathy, 1997; Lim et al., 1998). This 
modification has a striking implication in that many of the pregnant woman experience 
remission of autoimmune diseases like rheumatoid arthritis (RA) and multiple sclerosis that 
are Th1 mediated (Allebeck et al., 1984; Cutolo & Accardo, 1991). However the risk of 
systemic lupus erythematosis (SLE) in pregnant woman is much higher compared to non 
pregnant woman and this also has drastic effects on the survival of the foetus (Khamashta et 
al., 1997; Cooper et al., 2002;  Fraga et al., 1974).  
4.9 T and B-cell traffic in the CNS  
The migration of T-cells into the CNS adopt the same principles as they enter the peripheral 
tissues namely, activated T-cells migrate the tissues from the blood where as inactive  ones 
remains in the lymph vessels (Mackay et al., 1990). To demonstrate the migration of T-cells 
into the CNS, Hickey et al administered labelled T-cells intravenously and observed the 
appearance of T-cells in the brain parenchyma soon after 3 hrs (Hickey et al., 1991). Also, T-
cells in very minute levels were detected in the rat and human brains suggesting the fact 
that they continuously monitor the CNS (Pender, 1995).  Similarly B-cells cross the BBB, 
perhaps more rapidly than the T-cells and differentiate into the plasma cells in response to 
an antigen as they do in the periphery (Knopf et al., 1998; Anthony et al., 2003; Kanwar, 
2005). The following figure 3 represents the autoreactive T-cell entry and further 
consequences that lead to the generation of autoimmunity.  
4.10 Co-stimulatory molecules 
The phenomenon of T-cell activation and the generation of autoimmunity also depend on 
the involvement of several co-stimulatory molecules like B7-1, B7-2, CD28, inducible co 
stimulator (ICOS), OX 40 and CD40 ligand that are associated with T-cell activation. Other 
molecules like cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death 1 (PD-1) 
regulate negative co-stimulation. Hence, effective therapeutics targeting these molecules 
will have a significant impact in the autoimmune disease control (Racke & Stuart, 2002; 
Kanwar et al 2004). 
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Fig. 3. Schematic representation of autoimmune attack in the CNS APCs-Antigen presenting 
cells; BBB-Blood brain barrier; ICAM- intercellular cell adhesion molecule; MHC-Major 
histocompatibility complex; TCR-T-cell receptor; VCAM- Vascular intercellular cell 
adhesion molecule. 
The auto reactive T-cells gain entry into the CNS by the pairing of cell surface molecules 
leukocyte function-associated antigen-1 (LFA-1) and very late antigen-4(VLA-4) with the cell 
adhesion molecules, intercellular cell adhesion molecule (ICAM) and vascular cell adhesion 
molecule (VCAM) expressed on the brain capillary endothelium. Once after entry the helper 
T-cells (Th) bind with the processed peptide fragments presented along with MHC II by the 
antigen presenting cells (APCs).The threshold for triggering immune attack is lowered in 
autoimmune diseases and is stimulated by a variety of factors. The Th cells secrete a variety 
of cytokines that further activate the cytotoxic T-cells (Tc) and the antibody secreting B-cells. 
Tc cells, when activated mediate the cytotoxicity by releasing the granzymes while the B-
cells differentiate into plasma cells that produce auto antibodies against a variety of targets 
like the myelin, nicotinic acetylcholine receptors (NAchRs), voltage gated calcium channels 
(VGCC), voltage gated potassium channels (VGKC), glycolipids etc mediating the 
corresponding neurological autoimmune disorder. 
4.11 Autoimmunity and survivin 
In an effort to address issues involved with the treatment of neurodegenerative and 
autoimmune diseases, the two following strategies can be employed: a neuroprotection 
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strategy and a neuroproliferative strategy. Findings suggest that Bcl2 and IAP inducers are 
able to inhibit apoptosis for the purpose of neuroprotection in preclinical models (Kanwar, 
2010a-d, Baratchi, 2010 a&b). Our understanding of neurodegenerative diseases has 
improved over the past two decades. Whereas these disorders are initiated due to a range of 
insults such as reactive oxygen species or misfolded proteins, all of these pathologies end 
with a common consequence, which is the degeneration and deterioration of neuronal cells 
(Kanwar et al, 2010a). Despite all of the efforts to understand and treat neurodegenerative 
diseases, their successful treatment has still not been achieved. A proper treatment should 
not only protect neural cells but should also increase their proliferation and differentiation 
so as to provide a promising future for an aging population and families with a history of 
degenerative disorders, including multiple sclerosis, Parkinson’s disease and stroke. The 
brain’s environment is the most protected part of our body and neurons are a unique cell 
type (Baratchi, 2011a&b). Despite playing an important role in the analysis and transfer of 
information to the entire body, the lack of neural self-proliferation and repair highlights the 
importance of their protection and proliferation.  To be able to protect these cells from death 
and to facilitate their proliferation involves mechanisms that still need to be identified. 
Experimental findings achieved over the past few years have suggested that inhibitors of 
apoptosis (IAP), which serve a natural role in balancing cell death, might be candidate 
proteins with a unique potential for drug discovery (Kanwar et al, 2010). Recently we 
reviewed the exceptional capabilities of survivin (a unique member of IAPs) in both cell 
cycle and cell death pathways and its unique characteristics related to neuronal cell survival 
and proliferation (Baratchi, 2010a&b). 
Given that this is the first report of a protective effect of SurR9-C84A following an oxidative 
stress injury, further work should be done to study the effects of SurR9-C84A on in vivo 
models of degenerative diseases. In summary, we reported for the first time, a recombinant, 
cell-permeable form of the survivin mutant protein (SurR9-C84A) efficiently enters neuronal 
cells, protects differentiated SK-N-SH cells from the activation of apoptosis induced by 
H2O2, decreases the expression of cell cycle markers, and increases antioxidant activity. 
Emerging nano-delivery systems could be used to bypass the blood brain barrier, facilitating 
drug delivery to the damaged brain. Survivin is a member of the IAP family, which has been 
shown to have a role in early brain development and serves a bifunctional role during 
mitosis and inhibition of apoptosis (Baratchi et al., 2010a; Kanwar et al., 2010). Different 
forms of survivin mutants (such as C84A, Δ106 and T34A) have been used for the purpose 
of targeting survivin overexpression in cancer cells (Cheung, 2010a&b; Kanwar et al, 2010b; 
(Baratchi, 2010a&b). Among the various survivin mutants, the baculovirus IAP repeat motif 
(C84A) was initially produced and has since been shown to have proapoptotic effects on 
human cancer cells. Furthermore, we previously found that SurR9-C84A has protective 
effects against retinoic acid induced cell toxicity (Baratchi et al., 2011b). We used the SK-N-
SH cell line as a culture model of retinoic acid-induced neuronal differentiation (Baratchi, 
2010a&b). We showed for the first time, the neuroprotective effect of SurR9-C84A against 
cytotoxic elements existing in activated T-cell supernatants such as GrB. Because GrB is a 
powerful pro-apoptotic member of granzymes family and is a very important mediator of 
damage in progressive MS and other neuro-inflammatory disorders we examined the 
importance of GrB released from the activated T-cells in an in-vitro system and compared 
the protective effect of SurR9-C84A with GrB inhibitor (Baratchi, 2011a&b). SurR9-C84A can 
be applied in neuroprotective strategies to protect differentiated neural cells from cell cycle 
re-entry and apoptosis. Additionally, one important advantage of this mutant over the wild 
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type survivin is that it does not form tumour due to its pro-apoptotic effect in cancer cells. 
Because the over-expression of survivin has been reported in stimulated T-cells derived 
from patients with active MS, the neuroprotective ability of SurR9-C84A has the potential to 
be employed for future neurodegenerative therapies, and may also be further evaluated for 
targeting stimulated T-cells for the treatment of neurodegenerative diseases such as MS and 
other brain injuries (Baratchi, 2010a&b). 
5. Classification of autoimmune diseases 
Autoimmune diseases are characterised by the abnormal activation of the immune 
responses against our own tissues evidenced by the inability of the immune cells to 
differentiate self from non self antigens. Hence, mistakenly immune attack is directed 
towards our own body parts. They are categorised as systemic, involving multi target organ 
damage (e.g. systemic lupus erythematosis) or they can be localised involving damage to a 
single organ. (e.g. Type 1 diabetes) (Mackay & Rosen, 2001). 
A list of autoimmune neurological diseases are included and described as follows  (Dalakas, 
2006). 
5.1 Multiple sclerosis (MS)  
MS is a localised neurological autoimmune disease and is marked by the characteristic 
inflammation and degradation of the protective nerve lining, the myelin (Lucchinetti et al., 
2000; Lassmann, 2000). More than 1 million people are affected by MS with a characteristic 
presentation of weakness, abnormal senses, ataxia, poor balance, fatigue, vision loss and 
impaired cognition (Fugger et al., 2009; Kanwar et al 2004; Kanwar, 2005). Based on the 
histopathology multicentred inflammatory lesions were observed in the patient’s brain and 
the spinal cord (Frohman et al, 2006). Multiple aetiological factors are involved in the 
preponderance of the disease and are often found to be triggered by a viral infection 
(Lucchinetti et al., 2000). This initiation by an infection is by the process of molecular 
mimicry as discussed earlier. It is rather fascinating to study the generation of inflammatory 
lesions and the entry mechanisms of immune cells in MS. A specific population of activated 
T-cells that are selective towards myelin crosses the blood brain barrier under the strong 
influence of chemokines while the resting T-cells are inaccessible towards the BBB due to the 
unfeasible environment (Charo & Ransohoff, 2006). 
The cell surface molecules (integrins, selectins and cadherins) of the T-cells bind with the 
adhesion molecules expressed on the brain endothelial cells and finally escape into the CNS. 
Following their entry, the T-cells then direct the immune attack towards myelin antigen 
presented on their surface by the APCs (Greter et al., 2005). Along with macrophages, 
dendritic cells, glial cells and astrocytes present the MHC class II expression in the CSF and 
thus attract the T-cell traffic (Heppner et al., 2005; Greter et al., 2005). Under the influence of 
activated T-cells the immune attack is boosted up towards the myelin sheath and is executed 
by recruiting the T-cells and antibody secreting B-cells from the periphery driving the 
myelin assault leading to demyelination (Cepok et al., 2005; Steinman, 2002). The severity 
and progression of the demyelination process is influenced significantly by the B-cells as 
evidenced by the infiltration of macrophages and the deposition of immunoglobulins 
(Lucchinetti et al., 2000). The same was also supported by the observations made on clonal 
expansion and the presence of IgG complexes of B-cell populations in the brain and 
cerebrospinal fluid lesions (Qin et al., 1998; Baranzini et al., 1999; Colombo et al., 2000). The 
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whole process of immune attack and tissue damage is also encouraged by the active 
macrophages and glial cells (Brosnan & Raine,1996;  Heppner et al., 2005). Interesting results 
were obtained from the animal model of MS, experimental autoimmune encephalomyelitis 
where it was found that, the pro-inflammatory T cells of Th1-type were found to be 
responsible for the disease exacerbations (Wekerle et al., 1986;  Gold et al., 2006). There are 
four subtypes of MS and categorised as relapsing remitting (RR) with majority of the 
patients displaying recovery symptoms after disability. People who experience RR often 
complain a second variety of MS termed as secondary-progressive MS where the disability 
doesn’t subside between the cycles of relapses and recoveries. The third form is the primary 
progressive stage where there is only progression and no remission. The last form of MS is 
rather rare and termed as Progressive-relapsing MS (PRMS) characterised by the severe 
attacks and symptoms during the remission period (Mayoclinic, 2008). More than 1 million 
people are affected by MS with a characteristic presentation of weakness, abnormal senses, 
ataxia, poor balance, fatigue, vision loss and impaired cognition. Significant contributions 
are being made for the disease diagnostics and management with the introduction of 
potential biomarkers. There are findings of glial fibrillary acidic protein (GFAP) and 
neurofilament light protein (NFL) (the cytoskeletal proteins of astrocytes and axons 
respectively) release into the CSF during the disease progression (Axelsson et al., 2010).  
As per clinical data, the plasma levels of osteopontin was increased well before the 
induction of lesions with gadolinium (Gd) and  similar profiles were observed with 7KC and 
15 oxy sterol derivatives of cholesterol in MS patients. Added to this, enhanced antibody 
binding was reported towards these entities suggesting their potentials as biomarkers (Vogt 
et al., 2003; Whitaker, 1987). Also in a longitudinal cross sectional study of MS patients, it 
was found that levels of pentosidine, a well characterised biomarker for advanced glycation 
end products (AGE) were significantly elevated compared to the healthy controls. It was 
also observed that patients on treatment showed pentosidine down regulation compared to 
untreated patients. Thus, this study considers the AGE inhibitors as novel therapeutic 
interventions against MS. ( Sternberg et al., 2011) The recent reports on the associated tissue 
damage in MS patients found that it is not only limited to axons but also included 
significant retinal damage (Green et al., 2010). 
The current therapeutic strategies for MS include the treatment for disease progression and 
the symptoms. Interferon’s of type I (IFN-1) specifically marked as IFNb1a, IFNb1b and 
glatiramer acetate are considered as the first line drugs against RR form of MS but have a 
limited effectiveness. The mechanism of these drugs is that they down regulate the 
proliferation of T-cells, reduced antigen presentation, T-cell migration (interferon’s in 
particular) and shift the immune response to Th2 type (Clerico et al., 2007; Arnon & 
Aharoni, 2004).  Natalizumab, a humanized monoclonal antibody (mab) is found effective 
against MS as it inhibits the entry of T-cells into the CNS by acting against the cell surface 
molecule ǂ-integrins and showed significant reduction in the relapse rate compared to the 
above treatment strategies (Polman et al., 2006). However, limitation exists on its 
indiscriminate use as it poses a serious risk of brain infection, progressive multifocal 
leukoencephalopathy (PML) that even causes death (Clifford et al., 2010). Corticosteroids 
like prednisone, prednisolone, methyl prednisolone and dexamethasone are also used 
against the RR and rarely against secondary progressive multiple sclerosis as they act by 
suppressing the immune system. They are strictly contraindicated for long term use as they 
are associated with a number of side effects (Merck,). Chemotherapeutics with a potential of 
suppressing the immune system like mitoxantrone inducing the apoptosis of lymphocytes 
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and cyclophosphamide acting against both the T & B-cell activities, were also tried against 
RR and secondary progressive MS (Chan et al., 2005; Fauci et al., 1971; Multiple Sclerosis 
Treatments). The drugs in development for MS are Fingolimod and BG00012 that are in 
phase II clinical trials. Fingolimod acts by complexing the lymphocytes in the lymph nodes 
preventing their entry into the CNS and BG00012 is an oral formulation of Fumarate and 
presumed to act by neuroprotective and anti-inflammatory mechanisms inhibiting the 
oxidative stress (Lutterotti & Berger, 2010). Drugs in phase III clinical trials for RR form of 
MS are Laquinimod that acts by shifting the T-cell response to Th2 type and Teriflunomide 
acts by interrupting pyrimidine synthesis inhibiting the dihydro-orotate dehydrogenase and 
stops the expansion of T and B cells. Cladribine is efficient against both the resting and 
dividing T-cells and acts against the adenosine deaminase enzyme (Yang et al., 2004; 
Warnke et al., 2009). Monoclonal antibodies are also under evaluation and CAMPATH is 
tried against the CD52 expression on leukocytes. This activity depleted a majority of the 
lymphocytes, monocytes and dendritic cells in MS patients (Osborne, 2009; Hauser et al., 
2008). A similar effect was observed with Rituximab that acts against the CD20 expression. 
5.2 Myasthenia Gravis (MG) 
In the case of myasthenia gravis the prototypic B cells produce the auto antibodies that are 
directed against the nicotinic acetylcholine receptor (AchR) in the neuromuscular junction 
(NMJ) (Drachman, 1994; Ragheb & Lisak, 1998). These antibodies from the peripherally 
activated B cells infiltrate the end-plate region of NMJ, and down regulate the functionally 
active Ach receptors either by cross linking the receptor followed by internalization or by 
initiating the complement-mediated immune destruction or they may make the binding site 
unavailable for activity (Bufler et al., 1996). Following this, the signal transmission and 
communication is significantly affected between the neurons and the muscles in NMJ region 
due to the immune attack.  
Based on the symptom severity there are three subtypes of MG, Pure ocular MG 
characterised by weakness and fatigue of extra ocular muscles, resulting in ptosis and 
diplopia. Generalized MG, with extensive skeletal muscle weakness and finally myasthenia 
crisis, with disturbances in swallowing and respiratory failure (Hohlfeld et al., 2003). The 
exact role of antibodies in the pathogenesis of myasthenia gravis was confirmed from the 
results that, administration of myasthenic IgG antibodies generated the symptoms while the 
symptoms were ameliorated upon their removal (Drachman, 1994; Vincent et al., 2000). In a 
patient subgroup with myasthenia gravis, another variety of autoimmunity was reported 
with the detection of auto antibodies directed towards the muscle specific kinase. These 
patients were considered as seronegative to MG. (Vincent et al., 2003). The treatment 
modalities for MG include the acetylcholinesterase (AchE) inhibitors as the mainstay of 
treatment as they improve the bioavailability of Ach in the NMJ and the immune 
modulating agents. The AchE inhibitors of clinical significance are the pyridostigmine and 
neostigmine. They act by binding with AchE enzyme because of structural resemblance to 
Ach and slowly get hydrolysed compared to it. This improves the availability and 
subsequent binding of Ach to the available AchR in the NMJ. The common adverse effects 
associated are disturbances of GIT, respiratory system, cardiovascular system and glandular 
secretions (Kumar & Kaminski, 2011). 
5.2.1 Agents acting on immune system 
Glucocorticosteroids with a potential of strong anti-inflammatory and immunosuppressive 
activity are tried with a successful outcome. The orally administered glucocorticoids 
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(prednisone in common) show a delayed onset of action and take even months to exhibit 
maximum therapeutic benefit (Hohlfeld et al., 2003). However, intravenous administration 
is recommended for the management of exacerbations (Arsura et al., 1985). Long-term 
treatment is not recommended due to the severe side effects featuring crushing’s syndrome, 
obesity, precipitation of diabetes, gastrointestinal ulcers, opportunistic infections and 
hypertension etc. In the class of immune suppressive drugs, Azathioprine is the prominent 
and well tolerated drug tried against MG patients. This is a purine analogue and displays 
significant decrement in the levels of both T & B-cells thus monitoring the immune attack. 
Added to its mechanism it also exhibits anti-inflammatory actions by inhibiting 
promonocyte cell proliferation. It is generally given in combination to lower the dose of 
glucocorticoids but can also be prescribed alone for long term therapy (Mertens et al., 1981; 
Gold et al., 2003). Cyclosporine-A acts by binding to an intracellular protein, cyclophilin and 
forms a cyclosporine-cyclophilin complex. This complex exhibits immunosuppressive 
activity by inhibiting the phosphatase, calcineurin and prevents the cytokine formation. The 
clinical significance of this drug was that, it was the first drug tried in a double-blind and 
placebo-controlled trial MG patient population (Tindall et al., 1987). Patients with refractory 
MG show better responses towards cyclophosphamide, methotrexate and mycophenolate 
mofetil (Schneider-Gold et al., 2006). The recent advancements included are the 
administration of intravenous IgG that has a potential blocking activity against auto 
antibodies. This treatment is recommended when all the treatment modalities have failed. 
(Zinman et al., 2007) Advancements are made in the therapeutics of MG with the 
introduction of SHG2210, a novel entity with a potential to fuse with the ǂ-subunit of the 
auto antibodies that are directed against AchR. This SHG2210 -autoantibody fusion complex 
is later cleared by the transferrin receptor mediated cellular uptake (Keefe et al., 2010).  
On the whole due to the advancements made in the diagnosis and treatment, MG stands as 
a rear but treatable autoimmune disease. 
5.3 Guillainbarre syndrome (GBS) 
GBS is classified as an acute auto immune disease of demyelinating type mostly affecting 
the peripheral nervous system. Depending upon the target affected by the immune attack it 
is categorised to 4 subtypes. The first of its kind is the acute inflammatory demyelinating 
polyneuropathy (AIDP) where the immune attack is directed towards the myelin or 
schwann cell surface membrane. The next subtype is the acute motor axonal neuropathy 
(AMAN) targeting the axonal membrane in motor fibres where as both the motor and 
sensory nerve fibres are targeted in acute motor sensory axonal neuropathy (AMSAN). In 
the last subtype, distal nerve terminals and nodal regions of the ocular motor nerve are 
affected and termed as Miller Fisher syndrome (MFS) (Willison et al., 2002; Kuwabara, 
2004). GBS is often triggered by an infection of bacterial or viral origin with auto antibodies 
directed against gangliosides particularly in AMAN where infections with campylobacter 
jejuni produced auto antibodies against GM1, GM1b, GD1 or Ga1NAc-GD1a gangliosides 
(Ogawara et al., 2000). There were also detectable levels of IgG and complement deposition 
in the nerves (Hafer-Macko et al., 1996).  The distinct involvement of T and B-cells are 
identified in few subtypes, with the activated complement system playing a prime role in 
mediating demyelination and impaired conduction but still understanding the pathology of 
GBS remains rather elusive (Kieseier et al., 2004). The treatment for GBS is often confined to 
the immunomodulatory therapy where plasmapheresis and intravenous administration of 
immunoglobulin’s IVIg are given the priority (Dalakas, 1999; Hadden et al., 1998). 
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Plasmapheresis is the plasma exchange where the immunoglobulins and antibodies are 
removed from the serum with a subsequent separation of the blood cells. Then these blood 
cells are isolated and added to the fresh plasma or saline to administer back into the patient. 
IVIg operates through multiple mechanisms that include the inhibition of antibody 
production, complement binding, macrophage receptor blockade and the abnormal 
antibody neutralisation. Both these strategies were found to have equal efficiencies in 
reducing the disease progression (Heather Rachel Davids).. Future therapies for GBS are 
directed towards the complement inhibitors. (Walgaard et al., 2011) 
5.4 Neuromyelitis optica (NMO) 
The pathology of this neurological autoimmune disorder is clear with the detection of 
antibodies against the aquaporin -4 water channels of the endothelial cells in the CNS 
(Lennon et al., 2005). In the autopsy studies, deposition of Immunoglobulins particularly of 
the IgM subtype were detected in the lesions with activated complimentary system leading 
to vascular damage. The predominant immune attack directed in this disorder is of the 
humoral type with majority of the attack directed towards the optic nerve and the spinal 
cord (Lucchinetti et al., 2002; Wingerchuk et al., 2004; Bergamaschi, 2007). 
Immunosuppressive therapeutics like mycophenolate mofetil, mitoxantrone and rituximab 
are far beneficial rather than immunomodulating agents like interferons in 
NMO(Bergamaschi, 2007).Eculizumab, is a new molecule under Phase I/II clinical trials and 
the proposed mechanism for this entity is that it inhibits the complement activation and 
subsequent destruction (. clinicaltrials.gov.). 
5.5 Stiff-Man syndrome (SMS) 
Stiff man or Stiff-person syndrome is also a predominant antibody directed autoimmune 
disease with majority of the auto antibodies directed towards the enzyme, glutamic acid 
decarboxylase (GAD) that is essential for the synthesis of gamma-amino butyric acid, a 
principal inhibitory neurotransmitter in the brain. Also, detectable levels of 
Immunoglobulin belonging to the subtype IgG were found in the CSF confirming the 
infiltration of B-cells (Dalakas et al., 2001; Ishii, 2010). The recent epidemiological studies 
report the existence of anti-gephyrin, anti-amphiphysin and anti-gamma-aminobutyric acid 
A receptor-associated protein (GABARAP) antibodies in the disease pathology. The patients 
experiencing this disease complain symptoms of muscular rigidity in the legs and trunk 
region often associated with muscle spasms (Dalakas et al., 2000). The medication for stiff 
man syndrome initially should begin with the skeletal muscle relaxants benzodiazepine or 
baclofen. Intrathecal administration of baclofen was even considered in a selected patient 
group. However great care has to be taken in performing this procedure as it is involved 
with puncturing the meninges (Duddy & Baker, 2009). Other treatment options considered 
are plasmapheresis and administration of Intravenous immunoglobulins like Gamimune, 
Gammagard, Sandoglobulin (Dalakas, 2009; Hayashi et al., 1999). 
5.6 Paraneoplastic neurological syndromes (PNS) 
The pathology associated with this autoimmune disease is quite peculiar. Antigens that are 
confined to the nervous system are capable of mediating an immune attack if the same 
antigens are expressed in the case of pathological conditions such as the breast or ovarian 
cancers. The immune cells that are activated against these antigens also direct their attack 
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indiscriminately towards the antigens of the CNS that were once considered as self. A diverse 
range of self-antigens are identified in this setting and within this diversity, multiple epitopes 
are recognized within each antigen encountered. Thus, stimulated by the cancers, immune 
drive is targeted against the CNS evidenced by the detection of serum antibodies. The most 
common serum antibody detected is the anti-Hu antibody in patients coexisting with sensory 
neuropathy, encephalomyelitis or cerebellar ataxia (Dalmau et al., 1992; Graus et al., 2001; 
Darnell & Posner, 2003; Maverakis  et al., 2011). Other such auto antibodies detected are anti-
Yo antibodies in cerebellar degeneration (Peterson et al., 1992) anti-Ma1 and anti-Ma2 
antibodies in limbic encephalitis in patients with testicular cancer (Rosenfeld et al, 2001) and 
antibodies in Lambert-Eaton myasthenic syndrome in small cell lung cancer patients 
(Carpentier & Delattre, 2001). In the paraneoplastic autoimmune CNS disorders, immune cells 
penetrate the blood–brain barrier and the antibody mediated destruction serves as the 
dominant mode of immune attack as evidenced by the localised synthesis of antibodies by the 
B cells (Darnell & Posner, 2003 & Pranzatelli et al., 2004). However, defining the precise 
mechanisms of cellular and humoral pathways in the pathophysiology is still unclear and the 
immune system adapts the elusive mode to identify the intracellular antigens. 
The treatment for this disorder should be aimed at treating the underlying tumor with 
standard anticancer therapeutic regimen while the immune mediated disorder is treated by 
plasmapheresis or administration of immune suppressive drugs like Cyclosporine and 
glucocorticoids. Cyclosporine acts against both the cell and humoral mediated immune 
reactions and glucocorticoids are the potent anti-inflammatory and immune suppressive 
agents as discussed. Immune reaction suppression is even achieved by the administration of 
IVIg and Antithymocyte globulin is recommended in this case. It is a polyclonal IgG 
antibody particularly effective against T-lymphocytes and reduces the count to 85-90% 
(Buchwald et al., 2005; Koski & Patterson, 2006). 
5.7 Lambert-Eaton Myasthenic Syndrome (LEMS) 
Lambert-Eaton syndrome is a muscular disorder characterised by the autoantibody 
generation against the voltage gated calcium channels in the presynaptic nerve terminals. 
The communication is drastically affected between the nerves and muscles due to the 
inability of the nerve cells to release Ach required for muscular contraction. Hence, the 
symptoms of muscular rigidity and weakness are experienced in the patient population. The 
difference noticed between MG and LEMS is that in the latter form of the disease, with 
repeated contractions the muscle gets stronger for a shorter span of time instead of turning 
weaker (Lambert-Eaton syndrome, 2000). The primary treatment for LEMS aims to enhance 
the levels of Ach either by increasing its release or by inhibiting its metabolism thus making 
it available at the NMJ. The agents  that are considered effective in this regard are 
Pyridostigmine bromide, 3,4-Diaminopyridine (DAP) and guanidine HCl. Pyridostigmine is 
an AchE inhibitor and shows symptomatic relief, while DAP and guanidine HCL acts by 
enhancing the release of Ach with noticeable improvement in the muscular strength. 
Patients who are refractory to the above treatment are prescribed with the 
immunosuppressive drugs as mentioned earlier (McEvoy et al., 1989; Sanders, 1995). 
5.8 Neuromyotonia (NM) 
Neuromyotonia, is a rare autoimmune disorder with antibodies directed against the voltage 
gated K+ channels of the Shaker-type (Kv1). Based on the symptoms observed the disease is 
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categorised as acquired neuromyotonia (NMT) with peripheral nerve hyperexcitability, 
fasciculations and muscle stiffness. Morvan’s syndrome is associated with the symptoms of 
NMT along with encephalopathy and sleep disorders. The last subtype is the limbic 
encephalitis characterised by the CNS involvement with encephalopathic seizures, 
hyponatremia and abnormal electroencephalographic abnormalities. The antibodies noticed 
in this immune disorder were pathogenic and were confirmed by the observations of 
electrophysiological changes in mice, upon administration of IgG derived from patients 
(Kleopas et al., 2006; Buckley & Vincent, 2005; Merchut, 2010). Recently, a novel pathology 
was attributed to limbic encephalitis in which auto antibodies were identified against 
leucine-rich glioma-inactivated 1 (LGI1) protein. Previously, these auto antibodies were 
assumed to be acting against K+ channels and hence, this disorder is now termed as limbic 
encephalitis associated with LGI1 antibodies (Lai et al., 2010).  
Most of the patients with these disorders fairly respond when treated with 
immunosuppressive drugs like glucocorticosteroids. Also other recommendations include 
plasmapheresis and IVIg (Merchut, 2010). 
5.9 Polyneuropathies (PN) 
Polyneuropathies are divided into 3 subtypes as chronic inflammatory demyelinating 
polyneuropathy (CIDP), multifocal motor neuropathy (MMN) and IgM anti-myelin-
associated glycoprotein (MAG) demyelinating neuropathy (Kornberg & Pestronk, 2003;  
Czaplinski & Steck, 2004; Kieseier et al., 2004). Both the T and B-cell mediated immune 
havoc is noticed in CIDP with the majority of antibodies directed towards the glycolipids 
GM1 (Yan et al., 2000). Similar type of antibody production is identified against GM1 in half 
of the patient population in MMN but the pathogenecity of these antibodies are left 
unidentified (Nobile-Orazio, 2001). On the contrary, the IgM antibodies generated against 
the myelin associated glycoprotein in anti-MAG neuropathies are identified as pathogenic 
with a successful transfer of the disease to the animals. The normal cellular interactions were 
also found to be disturbed by these anti-MAG antibodies by the complement activation 
towards the myelin lamellae (Latov, 1994; Dalakas & Quarles, 1996; Quarles & Weiss, 1999). 
The treatment options considered are mainly immunosuppressive in nature and 
administration of glucocorticosteroids, plasmapheresis and IVIg are in use (Shy, 2007). 
Figure 4 summarises the pathologies of all the neurological autoimmune diseases. 
6. What’s in the pipeline? 
The role of B-cells in the autoimmune disorders is inevitable and considering this concrete 
paradigm researchers have now focussed targeting them with the mainstay of B-cell 
depletion. The targets identified were the B-lymphocyte stimulator (BLyS) protein and the 
CD20 expression on B-cells. Belimumab, is the humanised anti-BLyS monoclonal antibody 
and showed effective inhibition of invitro B-cell proliferation. (Baker et al, 2003) Also, phase 
I clinical trials of belimumab in SLE was well tolerated and further results are yet to be 
reported (Stohl, 2004). Rituximab, a chimeric anti-CD20 monoclonal antibody has the ability 
to deplete B-cells by multiple mechanisms and results are encouraging when it was tried 
against a variety of autoimmune disorders (Wylam et al., 2003; Ruegg et al., 2004;  Stuve et 
al., 2005).. In extension ocrelizumab, a humanized version of rituximab is currently in the 
developing stage for targeting several autoimmune disorders (Genovese et al., 2008). The 
same also holds true for Epratuzumab, a humanised mab that acts by blocking CD22 and 
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GAD-Glutamicacid decarboxylase; NAchR-Nicotinic acetylcholine receptors; VGCC- Voltage gated 
calcium channels; VGKC- Voltage gated potassium channels 
Fig. 4. Representing the various triggers of autoimmune diseases and the different targets 
involved in the generation of neurological autoimmune diseases. 
thereby depletes B-cell population (Dalakas, 2008). Targeting the T-cell antigens was always 
an area of intense interest. Researchers have made significant contributions with the 
development of anti-CD3 MAbs that displayed not only potent immunosuppressive 
activities but also the ability to restore self tolerance (Chatenoud, 2003). Progress was also 
presumed with the introduction of T-lymphocyte subsets, the invariant natural killer T 
(iNKT) cells. These unique cells stimulate a diverse range of cytokines that regulate the 
activities of various immune cells and thus prove to be handy for autoimmune disease 
therapeutics (Gabriel et al., 2010). The preclinical studies of methyl thioadenosine, a natural 
metabolite was found effective with its immunomodulatory activity in MS model. The 
results of this study showed an enhanced efficiency when it was combined with interferon’s 
or glatiramer acetate (Moreno et al., 2010). Midkine (MK) a cytokine that binds heparin is 
generally involved in inflammation by promoting T-cell traffic and cytokine up regulation.  
The MK inhibitors are assumed to be very valuable for treating MS as an aptamer to MK 
was found to repress experimental autoimmune encephalitis (Muramatsu, 2011). Histone 
deacetylase inhibitors were also found to have a potential against MS as they are found to 
interfere the immune system activation empowered with neuroprotective activities (Faraco 
et al., 2011). Recent advancements include the application of autologous and allogenic stem 
cell transplantations following intense immunoablation and the former application has 
lower toxicities compared to the latter. Encouraging results were obtained in a group of MS 
patients when treated with autologous stem cells compared to the existing therapies. 
However, further trials are warranted for the effective use (Marmont, 2000). 
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S. 
No 
Disorder
Immune attack 
directed to 
Current therapy Future drugs 
1 MS Myelin 
IFNb1a, IFNb1b, 
(Clerico et al., 2007) 
glatiramer acetate, 
(Arnon & Aharoni, 
2004)  
natalizumab, (Polman 
et al., 2006) 
glucocorticosteroids 
(Merck) and 
chemotherapeutics 
(Chan et al., 2005) 
Fingolimod, BG00012, 
(Lutterotti & Berger, 2010) 
Laquinimod 
Teriflunomide Cladribine 
(Yang et al., 2004; Warnke 
et al., 2009) 
Rituximab  
(Hauser et al., 2008) 
CAMPATH  
(Osborne, 2009) 
Midkine  
(Muramatsu, 2011) 
Methylthio-adenosine 
(Moreno et al., 2010) 
MAdCAM-1) antibody 
(Kanwar et al., 2004) 
Histone deacetylase 
inhibitors  
(Faraco et al., 2011) 
2 MG 
Nicotinic 
acetylcholine 
receptor and 
muscle specific 
kinase 
AchE inhibitors, 
(Kumar & Kaminski, 
2011) 
Glucocorticosteroids, 
(Hohlfeld et al., 2003) 
Azathioprine, (Mertens 
et al., 1981). 
cyclosporine, (Tindall 
et al., 1987) 
Cyclophosphamide 
and mycophenolate 
mofetil (Schneider-
Gold et al., 2006) 
SHG2210  
(Keefe et al., 2010) 
3 GBS 
Myelin and axonal 
membrane in 
motor and sensory 
fibres 
immunomodulatory 
therapy with 
plasmapheresis and 
IVIg (Dalakas, 1999; 
Hadden et al., 1998) 
Complement inhibitors 
(Walgaard et al., 2011) 
4 NMO 
Aquaporin -4 
water channels 
interferons , 
mycophenolate 
mofetil, mitoxantrone 
and rituximab 
(Bergamaschi, 2007) 
Eculizumab 
(clinicaltrials.gov) 
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5 SMS 
Glutamic acid 
decarboxylase 
enzyme 
skeletal muscle 
relaxants, (Duddy & 
Baker, 2009) 
Plasmapheresis and 
IVIg (Dalakas, 2009; 
Hayashi et al., 1999) 
------- 
6 PNS 
Hu, Yo,Ma1 & 
Ma2 antibodies 
Cyclosporine, 
glucocorticoids and 
Antithymocyte 
globulin (Buchwald et 
al., 2005; Koski & 
Patterson, 2006) 
------- 
7 LEMS 
Voltage gated 
calcium channels 
Pyridostigmine 
bromide, 3,4-
Diaminopyridine, 
guanidine HCl and 
immunosuppressive 
agents (McEvoy et al., 
1989; Sanders, 1995) 
------- 
8 NM 
Voltage gated K+ 
channels and 
leucine-rich 
glioma-inactivated 
1 protein 
Glucocorticosteroids, 
Plasmaoheresis and 
IVIg (Merchut, 2010) 
------- 
9 PN 
Glycolipid GM1 
and myelin 
associated 
glycoprotein 
Glucocorticosteroids, 
Plasmapheresis and 
IVIg (Shy, 2007) 
------- 
Multiple sclerosis=MS; Myasthenia gravis=MG; Guillain-Barre syndrome=GBS; Neuromyelitis 
optica=NMO; Stiff-Man syndrome =SMS; Paraneoplastic neurological syndromes=PNS; Lambert-Eaton 
myasthenic syndrome=LEMS; Neuromyotonia=NM and Polyneuropathies=PN 
Table 1. showing the disease mechanisms, current and future therapeutics for neurological 
autoimmune diseases. 
Targeting the immune cell entry is considered to be an ideal approach and based on this 
concept we noticed a significant blockade of lymphocyte traffic and eventual recovery in 
EAE mouse model when administered with mucosal addressin cell adhesion molecule 
(MAdCAM-1) antibody that binds with the integrins on the lymphocyte cell surface. We 
also developed a combinatorial approach for this model to protect the neurons against 
glutamate mediated damage with the ǂ-amino-3-hydroxy-5-methyl-4-isoxazolepropionate 
(AMPA)/ Kainate receptor antagonist 2,3-dihydroxy -6- nitro-7- sulfamoylbenzo 
(f)quinoxaline (NBQX), and the N-methyl D-aspartate (NMDA) receptor  antagonist 
GPE(neuro protector glycine-proline-glutamic acid;N-terminal tripeptide of insulin like 
growth factor ). This combinatorial therapy also helps in reducing the infiltrating immune 
cells at the site of inflammation in the brain (Kanwar et al, 2004).. We have also patented the 
treatment of demyelinating diseases by administering GPE (WIPO).In addition, there are 
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reports on the highly conserved BARF1 epitopes of Epstein Barr Virus with potent 
neuroprotective and mitogenic activities (Wynne et al., 2010). We, therefore anticipate 
conjugating antibodies with such neuroprotectors that would be definitely fruitful for 
treating a group of neurological autoimmune diseases. Application of nanotechnology also 
has a tremendous potential for their treatment, as the conjugation of nanoparticles with 
neuroprotectors and other therapeutics will significantly enhance the targeted delivery, 
bioavailability and efficacy. Finally introduction of locked nucleic acids (LNAs) has opened 
a new boom in the area of gene silencing. These LNAs are valuable nucleic acid analogues 
with striking abilities to regulate gene expression both in vitro and in vivo (Kauppinen et al., 
2005). Thus, in the near future they can be suitably modified to control the genetically 
mediated autoimmune diseases. Table 1 shows the comparison of current and future drugs. 
7. Conclusion 
Further to conclude, the immunosuppressive and anti-inflammatory treatments considered 
for treating autoimmune diseases pose serious side effects upon long term administration. 
Hence, it is rather expected, than to hope that emerging therapies based on the 
advancements made in  T and B-cell targeting would definitely complement or if not replace 
the existing therapies. It is worth mentioning to find many new novel entities that are in 
clinical trials for MS and other neurological autoimmune diseases. Inspite of these attractive 
therapeutic strategies strenuous efforts are to be made to identify the best possible 
candidates for effective disease control benefiting the patient population. 
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